This Stockhead article discusses the upcoming futility analysis for Actinogen Medical’s Phase IIb/III XanaMIA trial evaluating Xanamem as a potential treatment for Alzheimer’s disease.

Read the full article here: https://stockhead.com.au/health/health-check-actinogen-awaits-crucial-futility-ruling-on-alzheimers-disease-trial/